Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Su, Fei, Bradley, William D., Wang, Qiongqing, Yang, Hong, Xu, Lizhong, Higgins, Brian, Kolinsky, Kenneth, Packman, Kathryn, Kim, Min Jung, Trunzer, Kerstin, Lee, Richard J., Schostack, Kathleen, Carter, Jade, Albert, Thomas, Germer, Soren, Rosinski, Jim, Martin, Mitchell, Simcox, Mary Ellen, Lestini, Brian, Heimbrook, David, Bollag, Gideon · 2012 · Cancer Research

Abstract

A high percentage of patients with BRAFV600E mutant melanomas respond to the selective RAF inhibitor vemurafenib (RG7204, PLX4032) but resistance eventually emerges. To better understand the mechanisms of resistance, we used chronic selection to establish BRAFV600E melanoma clones with acquired resistance to vemurafenib. These clones retained the V600E mutation and no second-site mutations were identified in the BRAF coding sequence. Further characterization showed that vemurafenib was not able to inhibit extracellular signal-regulated kinase phosphorylation, suggesting pathway reactivation. Importantly, resistance also correlated with increased levels of RAS-GTP, and sequencing of RAS genes revealed a rare activating mutation in KRAS, resulting in a K117N change in the KRAS protein. Elevated levels of CRAF and phosphorylated AKT were also observed. In addition, combination treatment with vemurafenib and either a MAP/ERK kinase (MEK) inhibitor or an AKT inhibitor synergistically inhibited proliferation of resistant cells. These findings suggest that resistance to BRAFV600E inhibition could occur through several mechanisms, including elevated RAS-GTP levels and increased levels of AKT phosphorylation. Together, our data implicate reactivation of the RAS/RAF pathway by upstream signaling activation as a key mechanism of acquired resistance to vemurafenib, in support of clinical studies in which combination therapy with other targeted agents are being strategized to combat resistance. Cancer Res; 72(4); 969–78. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-1875

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 179

Metadata

Authors
Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., Lee, R. J., Schostack, K., Carter, J., Albert, T., Germer, S., Rosinski, J., Martin, M., Simcox, M. E., Lestini, B., Heimbrook, D., & Bollag, G.
Venue
Cancer Research
Published
2012-02-14
Volume
72
Issue
4
Pages
969-978
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2100887597
Cited by
179
References
8
FWCI
9.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-1875
The paper
Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., Lee, R. J., Schostack, K., Carter, J., Albert, T., Germer, S., Rosinski, J., Martin, M., Simcox, M. E., Lestini, B., . . . Bollag, G. (2012). Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-1875

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.